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Abstract Oxidation of fatty acids in mitochondria is a
key physiological process in higher eukaryotes including
humans. The importance of the mitochondrial beta-
oxidation system in humans is exemplified by the
existence of a group of genetic diseases in man caused
by an impairment in the mitochondrial oxidation of fatty
acids. Identification of patients with a defect in
mitochondrial beta-oxidation has long remained notori-
ously difficult, but the introduction of tandem-mass
spectrometry in laboratories for genetic metabolic
d i s e a s e sh a sr e v o l u t i o n a l i z e dt h ef i e l db ya l l o w i n gt h e
rapid and sensitive analysis of acylcarnitines. Equally
important is that much progress has been made with
respect to the development of specific enzyme assays to
identify the enzyme defect in patients subsequently
followed by genetic analysis. In this review, we will
describe the current state of knowledge in the field of
fatty acid oxidation enzymology and its application to
the follow-up analysis of positive neonatal screening
results.
Introduction
Fatty acids (FAs) constitute an important source of energy
in humans not only during fasting but also under well-fed
conditions, since some organs, including the heart, show a
marked preference for FAs at all times. Mitochondrial fatty
acid oxidation (FAO) is the principal pathway for oxidation
of FAs (Kunau et al. 1995), although FAs can also undergo
alpha- and omega-oxidation (Wanders et al. 2003). The
latter two pathways do not contribute much to the oxidation
of FAs in terms of energy production in human beings and
depend on beta-oxidation for further degradation of the
FAs. Importantly, in higher eukaryotes including humans,
beta-oxidation does not only occur in mitochondria but also
in peroxisomes. Oxidation in the two organelles proceeds
via a similar mechanism that involves four enzymatic steps
in which an acyl-coenzyme A ester (acyl-CoA) undergoes
subsequent steps of dehydrogenation, hydratation, another
dehydrogenation, and finally thiolytic cleavage. Despite
these similarities, there are major differences between the
two systems in terms of the enzymes involved, their
regulation, and the substrates handled by the two oxidation
systems. Indeed, it is clearly established that the bulk of the
dietary FAs including palmitic acid, oleic acid, and linoleic
acid are beta-oxidized in mitochondria. Peroxisomes,
however, play an equally indispensable role in whole cell
fatty acid oxidation, by catalyzing the beta-oxidation of a
range of FAs and fatty acid derivatives that are not handled
by mitochondria, which include very-long-chain FAs,
pristanic acid, and the bile acid intermediates di- and
trihydroxycholestanoic acid (Wanders and Waterham 2006).
The distinct physiological roles of the two beta-oxidation
systems is exemplified by the differences in clinical signs
and symptoms of patients affected by either a mitochondrial
beta-oxidation defect (Rinaldo et al. 2002) or a peroxisomal
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Table 1 lists the mitochondrial FAO-deficiencies currently
known with relevant information on the enzyme defects and
genes involved.
Enzymology of the mitochondrial beta-oxidation system
The FAs oxidized in mitochondria, may come from
different sources including (1) the diet, (2) de novo
synthesis, (3) release from adipose tissue, and (4) release
from different intracellular sites, including the peroxisome
and lysosome. Indeed, since peroxisomes are not able to
degrade FAs to completion, they release the chain-
shortened FAs either as free FAs or as carnitine ester
(Wanders and Waterham 2006), which are subsequently
taken up by mitochondria for full oxidation to CO2 and
H2O. Hydrolysis of macro-molecules in lysosomes mediat-
ed for instance by the enzyme palmitoyl protein thioester-
ase (PPT) also yields FAs as one of the end products.
The generally accepted notion holds that FAs are rapidly
activated to the corresponding CoA-esters by one of a
variety of different acyl-CoA synthetases of the long-chain
acyl-CoA synthetase (LACS) and very-long-chain acyl-
CoA synthetase (VLACS) subfamilies which reside in the
plasma membrane, mitochondria, peroxisomes and endo-
plasmic reticulum (Mashek et al. 2004;Watkins 2008).
Short- and medium-chain FAs are activated in the mito-
chondrial matrix (Mashek et al. 2004). The acyl-CoA esters as
such cannot traverse the mitochondrial inner membrane and
require the carnitine shuttle for this purpose (McGarry and
Brown 1997). Once inside the mitochondrion, the acyl-CoA
esters can be beta-oxidized to completion, and the end product
acetyl-CoA can be fully degraded to CO2 and H2Ov i at h e
Krebs cycle which also involves the active participation of the
mitochondrial oxidative phosphorylation system (Fig. 1).
Diagnostics by enzymatic analysis of the enzymes
involved in the carnitine cycle and mitochondrial
acyl-CoA beta-oxidation
In any patient suspected to suffer from a mitochondrial
beta-oxidation defect, enzymatic analysis needs to be done
to pinpoint the true underlying defect. In principle, there are
two scenarios: the first scenario is identification of the
Table 1 Characteristics of the mitochondrial beta-oxidation deficiencies
Deficiency Gene Protein
(abbreviation)
Gene
locus
Defect
described
Molecular defect
resolved
OMIM
Cellular uptake of carnitine and fatty acids
Plasma membrane carnitine transporter SLC22A5 OCTN2 5q33.1 1975 1998 212140
Long-chain fatty acid transporter ? ? ? 1998 – 600691
Mitochondrial carnitine cycle
Carnitine palmitoyltransferase 1 (liver form) CPT1A CPT1A 11q13 1981 1998 600528
255120
Carnitine acylcarnitine translocase SLC25A2 CACT 3p21 1992 1997 212138
Carnitine palmitoyltransferase 2 CPT2 CPT2 1p32 1973 1992 600649
255110
Mitochondrial beta-oxidation system
Very-long-chain acyl-CoA dehydrogenase ACADVL VLCAD 17p11 1993 1995 201475
Medium-chain acyl-CoA dehydrogenase ACADM MCAD 1p31 1982 1990 201450
Short-chain acyl-CoA dehydrogenase ACADS SCAD 12q22 1984 1990 201470
Isolated long-chain 3-hydroxyacyl-CoA
dehydrogenase
HADHA LCHAD 2p23 1989 1994 600890
Isolated long-chain 3-ketothiolase HADHB LCKAT 2p23 2006 2006 143450
Complete mitochondrial trifunctional protein HADHA LCHAD 2p23 1992 1995 600890
HADHB LCKAT 2p23 1992 1995 143450
Short-chain 3-hydroxyacyl-CoA dehydrogenase HADHSC SCHAD 4q22 2001 2001 601609
Medium-chain 3-ketoacyl-CoA thiolase ACAA2 MCKAT 1997 – 602199
ETF dehydrogenase ETFDH ETFDH 4q32 1985 1993 231675
ETF-alpha ETFA ETFα 15q23 1986 1991 608053
ETF-beta ETFB ETFβ 19q13 1991 1994 130410
2,4-dienoyl-CoA reductase DECR1 DECR1 8q21 1990 – 222745
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screening, the second is identification based on clinical
signs and symptoms in combination with a characteristic
acylcarnitine profile. Indeed, most of the currently
identified mitochondrial beta-oxidation deficiencies are
associated with distinct acylcarnitine profiles in plasma,
which are different for each of the individual beta-
oxidation defects (Fig. 2). The only exception to this
rule is CACT- versus CPT2-deficiency, which have
identical acylcarnitine profiles. In all other cases, the
acylcarnitine profiles usually suggest directly which step
in the mitochondrial beta-oxidation system is defective
(Fig. 2).
In order to rapidly identify the enzyme defect in
patients after the finding of an abnormal acylcarnitine
profile, we have set up enzyme activity measurements
for CPT1, CACT, CPT2, VLCAD, MCAD, SCAD,
LCHAD/MTP, and SCHAD in lymphocytes. This is
especially relevant since existing neonatal screening
programs have been extended in many countries around
the world including the Netherlands and now include
many of the mitochondrial beta-oxidation deficiencies.
We will now discuss the carnitine cycle plus the actual
beta-oxidation machinery in some detail including the
enzymes involved with particular emphasis on the
different enzyme assays currently in use for patient
diagnostics. Special attention will be given to the
enzyme assays developed in our own laboratory (see
Table 2 for details on each of these enzyme assays).
The mitochondrial carnitine cycle
The mitochondrial carnitine cycle involves the concerted
action of three distinct proteins including carnitine palmi-
toyltransferase 1 (CPT1), the mitochondrial carnitine/
acylcarnitine carrier (CACT), and carnitine palmitoyl
transferase 2 (CPT2). All three proteins are membrane-
bound, but there are notable differences. Indeed, CPT1 and
CACT, but not CPT2, are truly integral membrane proteins
with two and six transmembrane elements, respectively,
with CPT1 being localized in the mitochondrial outer
membrane and CACT in the mitochondrial inner mem-
brane. CPT2 is loosely associated with the inner face of the
mitochondrial inner membrane (Fig. 1).
CPT1 is the only enzyme of the mitochondrial fatty
acid oxidation system that is known to exist in tissue-
specific isoforms. The genes for liver-specific L-CPT1
and muscle specific M-CPT1 are on chromosomes
11q13 and 22q13.3, respectively, and each of the two
genes encodes a 88-kDa polypeptide with 63% identity.
They differ in kinetic properties such as inhibitor
constants for malonyl-CoA (McGarry and Brown 1997)
and the Km for L-carnitine.
CACT is a homo-dimer of two 33-kDa polypeptides,
and is required for the transport of acylcarnitines
(formed by CPT1) into the mitochondrion in exchange
for free carnitine. The carnitine cycle is completed by
CPT2 that reconverts the acylcarnitine back into the
corresponding acyl-CoA, which is then substrate for the
Fatty acid
Cell membrane FATP FAT / CD36
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Carnitine
Carnitine
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Fig. 1 Schematic representation
of the mitochondrial fatty acid
beta-oxidation pathway. The
pathway starts with the uptake
of FAs and carnitine from the
plasma compartment into the
cell, followed by the transport of
acyl-CoA esters into the mito-
chondria via the carnitine cycle
and the actual stepwise degra-
dation of acyl-CoAs via the
beta-oxidation spiral with
acetyl-CoA units as end product,
which can either be converted
into ketone bodies or combusted
in the citric acid cycle to CO2
and H2O
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also accepts and transports short-chain acylcarnitines,
such as acetylcarnitine and propionylcarnitine produced
in peroxisomes (Wanders and Waterham 2006). Conver-
sion of these two carnitine esters into acetyl-CoA and
propionyl-CoA is not mediated by CPT2 but by the short-
chain-specific enzyme carnitine acetyltransferase (CRAT).
Interestingly, the carnitine cycle may also work in the
reverse direction, which allows the export of acyl-CoA
esters in the form of an acylcarnitine ester to the extra-
mitochondrial space and subsequently into the extra-
cellular space (Ventura et al. 1998).
Enzymatic analysis of the carnitine cycle
CPT1
CPT1 catalyses the following reaction:
acyl CoA þ carnitine ! acylcarnitine þ CoASH:
Currently, only deficiencies of liver CPT1 have been
reported. Fortunately, this CPT1 isoform is expressed in
fibroblasts and lymphocytes. In principle, there are several
ways to measure the activity of CPT1. A frequently used
method involves incubation of freshly prepared tissue
homogenates (Demaugre et al. 1988), isolated mitochon-
dria, or selectively permeabilized cells (Schaefer et al.
1997) in a medium containing palmitoyl-CoA plus [
14C]-
labeled carnitine, followed by extraction of the [
14C]-
labeled acylcarnitine using water-saturated butanol at the
end of the incubation period. Incubations are usually
performed in the presence and absence of malonyl-CoA
(>100 μmol/L) and the malonyl-CoA-inhibitable activity is
taken to represent true CPT1-activity. We have been using
this method to determine the activity of CPT1 in
cultured skin fibroblasts using digitonin to permeabilize
the plasma membrane for quite a few years. Recently,
however, we came across some serious pitfalls of this
assay, one being the fact that the acylcarnitine produced
by CPT1 turned out to undergo appreciable further
oxidation (van Vlies et al. 2007). The implication of this
finding was that the activity of CPT1 had been under-
estimated considerably. We have studied this phenome-
non in detail and have found out that this problem
could simply be overcome by addition of KCN, an
inhibitor of cytochrome C oxidase and thereby of the
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acyl-CoA (n-2) + acetyl-CoA
acylcarnitines
C16:0 , C18:1  , C18:2  , C18:0 
C16:0 , C18:1  , C18:2  , C18:0 
C14:0 , C14:1  , C16:0  , C16:1 
C16:2 , C18:0  , C18:1  , C18:2 
C6:0 , C8:0  , C10:0  , C10:1 
C4:0
C16:0OH , C16:1OH 
C18:0OH ,  C18:1OH 
Free carnitine acylcarnitines
VLCAD
MCAD
SCAD
LCHAD
SCHAD
LCKAT
C4:0OH 
CACT
CPT1
3-OHacyl-CoA dehydrogenases
3-ketoacyl-CoA thiolases
C16:0OH ,  C16:1OH  plus  long-chain
C18:0OH ,  C18:1OH 3-ketoacylcarnitines
Fig. 2 Overview of the different mitochondrial fatty acid beta-oxidation deficiencies and the plasma acylcarnitine abnormalities identified in each
of them
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tion of KCN blocked further oxidation of palmitoylcar-
nitine completely (van Vlies et al. 2007). With KCN
present in the assay medium CPT1 activities as measured
in fibroblasts were approximately two-fold higher as
compared to assay conditions without KCN (van Vlies et
al. 2007). It should be noted, however, that this finding
does not mean that the previously used method was not
suitable for diagnosing patients with deficiencies of CPT1.
In order to avoid the use of radioactive chemicals, we have
modified the assay and turned it into a highly sensitive,
non-radioactive tandem-MS-based assay by using
[U-
13C]-palmitoyl-CoA rather than [1-
14C]-palmitoyl-
CoA. The assay was validated by measuring the activity
of CPT1 in cell lines of five patients with a full,
genetically confirmed deficiency of CPT1, which revealed
no detectable CPT1 activity (van Vlies et al. 2007). We
have been using this assay for a few years now and have
found that it is a very robust and powerful method.
Although it is not a standard procedure, the assay can also
be applied to cell and tissue homogenates.
CACT
CACT catalyzes the transport of carnitine and acylcar-
nitines of various chain lengths by an exchange
mechanism (Palmieri 2004). CACT activity can only be
measured either in freshly prepared mitochondria, or in
selectively permeabilized cells which is the method
preferred by ourselves. Murthy et al. (1986) developed
an assay for the carnitine/acylcarnitine translocase
applicable to biopsied specimens without requiring
isolation of mitochondria. This method was adapted by
Pande et al. (1993) and modified to allow measurement
Table 2 Enzymatic analysis of the different mitochondrial fatty acid beta-oxidation enzymes and the experimental conditions used in our
laboratory for each of these enzymes
Enzyme/
transporter
Assay
medium
Incubation
period and
temperature
Method of
analysis
Reference
CPT1 150 mmol/L KCl, 25 mmol/L Tris, 2 mmol/L
EDTA, 20 mmol/L potassium phosphate,
1 mg/mL bovine serum albumin, 4.5 mmol/L
GSH, 5 mmol/L KCN, 50 μg/mL digitonin,
0.5 mmol/L carnitine, pH=7.0, plus 25
μmol/L [U-
13C]-palmitoyl-CoA
10 min, 37°C Tandem-MS (van Vlies
et al. 2007)
CACT 150 mmol/L KCl, 25 mmol/L Tris-HCl, 2.0
mmol/L EDTA, 10 mmol/L potassium
phosphate, 10 mg/mL bovine serum albumin,
40 μg/mL digitonin, pH=7.4 plus 0.1 mmol/L
acetylcarntinine and [1-
14C]-acetylcarnitine
30 min, 25°C Radiometry
(
14CO2 release)
(IJlst et al.
2001)
CPT2 100 mmol/L Tris-HCl, 120 mmol/L KCl, 5
mmol/L GSH, 8 mmol/L CoASH, 2 mmol/L
palmitoyl-carnitine, 0.2% (w/v) Triton X-100,
pH=7.0
20 min, 37°C HPLC-UV To be
published
VLCAD 125 mmol/L Tris-HCl, 0.4 mmol/L ferricenium
hexa-fluorophosphate, 0.25 mmol/L palmitoyl-
CoA, pH 8.0
5 min, 37°C HPLC-UV To be
published
MCAD 200 mmol/L Tris-HCl, 0.22 mmol/L 3-
phenylpropionyl-CoA, 0.4 mmol/L
ferricenium hexafluorophosphate, pH=8.0
10 min, 37°C HPLC-UV To be
published
LCHAD 100 mmol/L potassium phosphate, 50 mmol/L
MOPS, 0.1 mmol/L DTT, 0.1% (w/v) Triton
X-100, 0.15 mmol/L NADH, 5 mmol/L
N-ethylmaleimide (if added), pH=6.16,
plus 50 μmol/L 3-ketopalmitoyl-CoA
Continuous
assay, 37°C
Spectrophotometry
(340 nm)
(Wanders
et al. 1990)
LCTH 100 mmol/L Tris-HCl, 10 mmol/L MgCl2,
50 μmol/L CoASH, pH=8.05, plus 50
μmol/L 3-ketopalmitoyl-CoA
Continuous
assay, 37°C
Spectrophotometry
(303 nm)
(Wanders
et al. 1990)
SCHAD 100 mmol/L potassium phosphate, 50 mmol/L
MOPS, 0.1 mmol/L DTT, 0.1% (w/v) Triton
X-100, 0.15 mmol/L NADH, 5 mmol/L
N-ethylmaleimide (if added), pH=6.16,
plus 50 μmol/L acetoacetyl-CoA
Continuous
assay, 37°C
Spectrophotometry
(340 nm)
(Wanders
et al. 1990)
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digitonin as permeabilizing agent. This assay measures
the formation of [
14C]-acetylcarnitine from added [2-
14C]-
pyruvate in the mitochondrion and requires the active
participation of the pyruvate transporter, pyruvate dehy-
drogenase, CRAT, and CACT to allow uptake of carnitine
(needed in the CRAT reaction) in exchange for radio-
labeled acetylcarnitine (Fig. 3a). Furthermore, malonate
was added to the incubation medium to prevent degrada-
tion of acetyl-CoA in the Krebs cycle by inhibiting
succinate dehydrogenase and thereby blocking the gener-
ation of oxaloacetate (Fig. 3a).
As an alternative to the use of radiolabeled pyruvate,
which may be troublesome at times, we have developed a
different method in which the formation of [
14C]-CO2 from
[1-
14C]-acetylcarnitine is measured to determine CACT
activity (IJlst et al. 2001). The principle of our method is
that the [1-
14C]-acetylcarnitine enters the mitochondrion via
CACT followed by the conversion of [1-
14C]-acetylcarni-
tine into [1-
14C]-acetyl-CoA catalyzed by CRAT after
which the radiolabeled acetyl-CoA is oxidized in the Krebs
cycle generating [
14C]-CO2 (Fig. 3b).
Although the two methods developed by Pande et al.
(1993), Murthy et al. (1986) and ourselves (IJlst et al.
2001) work very well in practice, a drawback of the two
methods is that both assays are not true single-enzyme (or
in this case single-transporter) assays since both methods
require the active participation of a number of additional
auxiliary enzymes (Fig. 3). There is definitely a need for a
single one-step assay.
CPT2
Since the reaction catalyzed by CPT2, i.e. palmitoylcarnitine
+C o A S H→ palmitoyl-CoA + carnitine, is readily reversible,
the activity of CPT2 can be measured either in the forward or
backward reaction. The notion that long-chain acylcarnitines
can easily be extracted from aqueous solutions by means of
butanol has led to the development of a very popular assay in
which tissue homogenates, mitochondria, or membrane
preparations are incubated in a medium containing radio-
labeled carnitine and palmitoyl-CoA plus a detergent like
Triton X-100 to inactivate CPT1, followed by extraction of
radiolabeled palmitoylcarnitine. Although this method
works fine, alternative assays have been developed in
which CPT2 is measured in the forward, physiological
direction like we do in our laboratory (see Table 2). An
important reason for this is that the maximal rate of CPT2
in the forward reaction is markedly higher than in the
reverse direction. In fibroblasts from CPT2-deficient
patients with either deletions or mutations in the CPT2
gene leading to premature stopcondons, the activity of
CPT2 is fully deficient using the assay developed in our
laboratory.
Carnitine CoASH
MIM
Carnitine
Digitonin permeabilized
plasma membrane
Mitochondrion
MOM
[2-14C]-pyruvate
[2-14C]-pyruvate
[2-14C]-pyruvate
[14C]-acetyl-CoA CRAT
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PDH
CACT
[14C]-acetylcarnitine
Krebs
Cycle
Succ
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A
[14C]-acetylcarnitine
[14C]-acetylcarnitine
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14CO2
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Cycle
CoASH
B
[1-14C]-acetylcarnitine
[1-14C]-acetylcarnitine
[1-14C]-acetyl-CoA
Matrix
Fig. 3 Principal features of two carnitine acylcarnitine translocase
(CACT) activity assays. a The method devised by Pande and co-
workers involves the use of [2-
14C]-pyruvate with [
14C]-acetylcarni-
tine as end product (Murthy et al. 1986). b The assay developed by
IJlst et al. (2001) measures the formation of radiolabeled CO2 from
[
14C]-acetylcarnitine
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literature, including the one described by Rettinger et al.
(2002). In this elegant and powerful assay, a coupled reaction
system is used in which the carnitine produced from
palmitoylcarnitine in the CPT2 reaction is directly converted
into acetylcarnitine, which is then quantified by tandem
mass-spectrometry.
The mitochondrial fatty acyl-CoA oxidation system
The actual beta-oxidation process involves the concerted
action of multiple enzymes present in mitochondria. For the
oxidation of straight-chain acyl-CoAs like palmitoyl-CoA,
a series of chain-length specific acyl-CoA dehydrogenases
(ACADs), enoyl-CoA hydratases (EHs), 3-hydroxyacyl-
CoA dehydrogenases (3HADs), and 3-ketoacyl-CoA thio-
lases (KATs) are required to catalyze the cyclic release of
acetyl-CoA units (Fig. 1).
Oxidation of branched-chain fatty acids as well as
unsaturated fatty acids requires the participation of a
range of auxiliary enzymes, including 2-methylacyl-CoA
racemase, Δ3,Δ2-enoyl-CoA isomerases, 2,4-dienoyl-
CoA reductases, and Δ
3,5, Δ
2,4 dienoyl-CoA reductases,
which will not be discussed here (see Hiltunen and Qin
2000 for review).
Acyl-CoA dehydrogenases
Studies in the 1950s (see Beinert 1990 for review) have led
to the identification of three different ACADs each having
specific substrate specificities referred to as short-chain
(SCAD), medium-chain (MCAD), and long-chain (LCAD)
acyl-CoA dehydrogenase (Fig. 4a). All enzymes are homo-
tetramers, localized in the mitochondrial matrix, with a
native molecular weight of 160–180 kDa with each subunit
carrying a flavin adenine dinucleotide (FAD) bound non-
covalently to the enzyme. It was long thought that LCAD
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Fig. 4 Substrate specificities of the different mitochondrial beta-
oxidation enzymes. a Reactivity of the different rat acyl-CoA
dehydrogenases with acyl-CoA esters ranging from C4:0 to C24:0-
CoA (SCAD, MCAD, and VLCAD). Data compiled from Furuta et al.
(1981, Izai et al. (1992) and Ensenauer et al. (2005). b Reactivity of
crotonase and the long-chain enoyl-CoA hydratase component of
MTP as purified from rat liver with α, β-unsaturated acyl-CoAs
ranging from C4 to C16. c Reactivity of SCHAD and the LCHAD-
component of MTP as purified from rat liver with 3-ketoacyl-CoAs
ranging from C4 to C16. d Reactivity of medium-chain 3-ketoacyl-
CoA thiolase and the long-chain 3-ketoacyl-CoA thiolase component
of MTP as isolated from rat liver with 3-ketoacyl-CoAs ranging from
C4 to C16. Data taken from Izai et al (1992)
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of long straight-chain acyl-CoAs. This was later disproven
(Yamaguchi et al. 1993) and resolved by Bertrand et al.
(1993) and Aoyama et al. (1993) following the discovery of
a new acyl-CoA dehydrogenase, named VLCAD, by
Hashimoto and co-workers (Izai et al. 1992). VLCAD is a
dimer of two identical subunits bound to the inner
mitochondrial membrane (Fig. 1) and accepts long chain
acyl-CoAs as substrate (Fig. 4a).
The different ACADs catalyze the following reaction:
acyl CoA þ FAD ! trans 2 enoyl CoA þ FADH2
It is now clear that oxidation of long straight-chain
acyl-CoAs involves the subsequent action of VLCAD,
MCAD, and SCAD, respectively, with virtually no
contribution of LCAD in humans. In rodents, however,
LCAD does play a significant role in FAO (Chegary et
al. 2009). In addition to the four ACADs described above,
a number of additional ACADs have been identified of
which ACAD9 has been claimed to play a prominent role
in the oxidation of long-chain FAs in human brain. Indeed,
studies by Vockley and co-workers (Ensenauer et al. 2005)
have shown that ACAD9 is highly expressed in human
brain, and is mostly localized to subpopulations of
neurons in which LCHAD/MTP is also expressed, most
notably in the cerebellum (He et al. 2007). The finding
that the substrate specificity of ACAD9 mimics that of
VLCAD, in combination with the observation that
ACAD9 is, in fact, expressed in the CNS in humans
and the chronic neurological abnormalities in the
ACAD9-deficient patients reported by He et al. (2007),
provide support for a previously unappreciated but
important role of ACAD9 in the mitochondrial beta-
oxidation of long-chain fatty acids in neuronal tissue. In
fibroblasts, ACAD9 is well expressed but does not
contribute to long-chain acyl-CoA dehydrogenase activity
using palmitoyl-CoA as substrate as discussed later in this
review.
Enoyl-CoA hydratases
EHs catalyze the following reaction:
trans 2 enoyl CoA þ H2O $ L 3 hydroxyacyl CoA:
Mitochondria contain different EHs of which the short-chain
enoyl-CoA hydratase (alternative name: crotonase), and long-
chain enoyl-CoA hydratase, as part of the mitochondrial
trifunctional protein (MTP) are involved in the oxidation of
long straight-chain acyl-CoAs. Crotonase acts on 2-enoyl-
CoAs ranging from crotonyl-CoA (C4:1-CoA) to 2-trans-
hexadecenoyl-CoA (C16:1-CoA) with decreasing efficiency.
The latter substrate is only hydrated at a rate of 1–2% of that
of crotonyl-CoA (Fig. 4b). Crotonase catalyzes the cis-
addition of H2O and also accepts 2-cis-enoyl-CoAs as
substrates, converting them into D-3-hydroxyacyl-CoAs.
The long-chain enoyl-CoA hydratase as part of MTP shows
highest activity with the C16:1 substrate whereas activity
with the C6:1 substrate and especially C4:1 (crotonyl-CoA)
substrate is virtually zero, suggesting that crotonase is
required, at least for the hydratation of crotonyl-CoA
(Fig. 4b). The fact that crotonase shows high activity with
the C4:1 substrate but not the C16:1 substrate, whereas the
reverse is true for the long-chain enzyme, allows easy
discrimination between the two enzymes in tissue prepara-
tions, fibroblasts and other cells.
3-Hydroxyacyl-CoA dehydrogenases
3HADs catalyze the following reaction:
L 3 hydroxyacyl CoA þ NADþ
! 3 ketoacyl CoA þ NADH:
Mitochondria contain different 3HADs, including a
short-chain 3-hydroxyacyl-CoA dehydrogenase
(SCHAD) and long-chain 3-hydroxyacyl-CoA dehydro-
genase (LCHAD) as part of MTP. Both enzymes are
required for the proper oxidation of long straight-chain
acyl-CoAs. SCHAD shows broad activity with 3-
hydroxyacyl-CoAs ranging from C4 to C16, whereas
the LCHAD component of MTP shows highest activity
with the C16 substrate with virtually no reactivity with
the C4 substrate (Fig. 4c), suggesting that SCHAD is
indispensible at least for the oxidation of the C4 substrate.
This is in line with the findings in SCHAD- versus
LCHAD-deficient patients as discussed later.
3-Ketothiolases
KATs catalyze the following reaction:
3 ketoacyl CoA þ CoASH
! n   2 ðÞ acyl CoA þ acetyl CoA:
Mitochondria contain at least three KATs. For the proper
oxidation of long straight-chain acyl-CoAs, the long-chain
thiolase (LCKAT) as part of MTP is essential, as demon-
strated by the findings in patients with isolated LCKAT
deficiency (Das et al. 2006) as well as in patients with a full
deficiency of MTP (Wanders et al. 1992). The long-chain
thiolase of MTP is reactive with a range of 3-ketoacyl-
486 J Inherit Metab Dis (2010) 33:479–494CoAs ranging from C16 tot C6 with no activity with the C4
substrate (Fig. 4d).
The second mitochondrial thiolase was initially called
“general thiolase”, but has later been renamed into medium-
chain 3-ketothiolase (MCKAT) by Kamijo et al. (1997).
The function of this thiolase in fatty acid beta-oxidation
remains to be established despite the fact that Kamijo et al
(1997) described a patient with a presumed defect at the
level of MCKAT. In the absence of any definitive proof
which includes molecular analysis of the underlying gene,
it remains to be established whether MCKAT is truly
deficient in this patient.
Mitochondria also contain a third thiolase often referred
to as “beta-ketothiolase” with 2-methylacetoacetyl-CoA as
unique substrate. This thiolase does not play any role in
FAO but is indispensable for isoleucine degradation
(Mitchell and Fukao 2001).
All the enzymes described above have been purified,
characterized and cloned. The mitochondrial trifunctional
protein has been purified from different sources (Uchida et
al. 1992; Carpenter et al. 1992; Luo et al. 1993) and is a
hetero-octamer of 4 alpha-and 4 beta-subunits with the
alpha-subunit (79 kDa) carrying the enoyl-CoA hydratase
activity and 3-hydroxyacyl-CoA dehydrogenase activity,
whereas the beta-subunit harbours the thiolase component
(Uchida et al. 1992).
Enzymatic analysis of the mitochondrial acyl-CoA
beta-oxidation system
Acyl-CoA dehydrogenases
The specific measurement of each of the individual ACADs
in a mitochondrial preparation, or preferably in total cell
homogenates, requires at least two things: (1) a specific
substrate preferably reactive with only one particular
ACAD; and (2) a specific detection system allowing the
activity of each ACAD to be measured. The first condition
is only met for MCAD if 3-phenylpropionyl-CoA is used as
substrate since 3-phenylpropionyl-CoA is a unique sub-
strate for MCAD (Lehman et al. 1990). Although
palmitoyl-CoA is a substrate for multiple ACADs (see
Fig. 4a), we and others have found that palmitoyl-CoA is a
specific substrate for VLCAD in homogenates of cultured
skin fibroblasts and lymphocytes. This is concluded, among
others, from the observation that the acyl-CoA dehydroge-
nase activity measured with palmitoyl-CoA as substrate is
fully deficient in fibroblasts (Fig. 5a) and in lymphocytes
(Fig. 5b) from patients with genetically confirmed
VLCAD-deficiency (Fig. 5a). This indicates that ACAD9
does not contribute to the palmitoyl-CoA dehydrogenase
activities in these cell types despite its significant expres-
sion levels. For SCAD, a specific substrate which is not
handled by any of the other ACADs has not yet been
identified. Butyryl-CoA is usually used as substrate. Since
butyryl-CoA is also a substrate for other ACADs (Fig. 4a),
corrections have to be made for the contribution by the
other ACADs. One method which we favor in our
laboratory is to measure the butyryl-CoA dehydrogenase
activity in homogenates before and after immuno-
precipitation of SCAD using a specific antibody (Wanders
et al., in preparation).
In the early years, acyl-CoA dehydrogenase activities
were measured fluorimetrically and/or spectrophotometri-
cally using different dye-reduction assays, which are based
on the use of artificial electron acceptors such as
dichlorophenol-indophenol (DCPIP) with either phenazine
methosulphate (PMS) or ETF (Rhead et al. 1983)a s
mediator. These types of assays have a number of draw-
backs, including the relatively high background plus the
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Fig. 5 Results of VLCAD activity measurements in fibroblasts (a) and lymphocytes (b) from controls and genetically proven VLCADD-patients
J Inherit Metab Dis (2010) 33:479–494 487fact that only isolated mitochondria or even more purified
fractions can be used in the assay. Although different
improved variations on this theme have been devised
(Dommes and Kunau 1976), there was a clear need for new
assays. One was the ETF-based assay, which has remained
the method of choice for many years for measurement of
SCAD, MCAD, and VLCAD in patients’ cells (Stanley et al.
1983;C o a t e se ta l .1985). Oxidized ETF is highly
fluorescent, and this fluorescence is lost upon the reduction
of ETF by any of the acyl-CoA dehydrogenases, thus
yielding a sensitive and accurate technique. Unfortunately,
ETF has never become commercially available and, in
addition, the assay needs to be done anaerobically, which
in practice yields problems. For this reason alternative assays
have been devised including the tritium-release assay for
MCAD using [2,3-
3H]-octanoyl-CoA as substrate (Amendt
and Rhead 1985).
Kolvraa et al. (1982) were the first to device a
completely different method based on the identification of
the products of the ACAD reaction, in their case MCAD,
using gas chromatography-mass spectrometery. Different
variations on this theme have been published by several
authors (Niezen-Koning et al. 1992, 1994; Duran et al.
1992).
In 1990, Lehman and Thorpe (1990) published a direct
spectrophotometric method for MCAD based on the use of
ferricenium hexafluorophosphate. The method involves
measurement of the 3-phenylpropionyl-CoA mediated
reduction of the ferricenium ion at 303 nm. We have
adopted the same principle to measure the activity of
VLCAD (IJlst et al. 1994). However, it soon turned out that
these spectrophotometric methods for MCAD and VLCAD,
respectively, lack robustness and sensitivity, and, more
importantly, lead to artificially high residual activities,
amounting to 50% of normal in fibroblasts from patients
with a full deficiency of MCAD (Taylor et al. 1992).
Similar high residual activities were found for VLCAD in
fibroblasts using the ferricenium-based assay in fibroblasts
from patients with a full deficiency of VLCAD (IJlst and
Wanders 1993a).
Since ferricenium hexafluorophosphate was (and is)
commercially available, we (Wanders et al. 1999; Oey et
al. 2006) devised a new type of assay for measurement of
ACAD activities, which involves the use of ferricenium
hexafluorophosphate as electron acceptor followed by the
analysis of the products of the ACAD reaction by HPLC
coupled to UV-detection or by UPLC coupled to tandem-
MS detection (Table 2). This method is now also used by
others (Spiekerkoetter et al. 2003; Tajima et al. 2005, 2008;
ter Veld et al. 2009). We have been using this assay for
VLCAD, MCAD, and SCAD analysis (see Table 3).
Moreover, we are using the same methodology for the
analysis of other ACADs, which include glutaryl-CoA
dehydrogenase, isovaleryl-CoA dehydrogenase, short
branched-chain acyl-CoA dehydrogenase, and ACAD8.
Figure 6 shows typical HPLC/UV chromatograms of our
MCAD assay for fibroblasts (Fig. 6a) and lymphocytes
(Fig. 6b) from control subjects and MCAD-deficient
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Fig. 6 HPLC/UV-chromatograms of extracts, prepared from incuba-
tions in which fibroblasts (a) or lymphocytes (b) from control and
genetically proven MCADD-patients were incubated with 3-
phenylpropionyl-CoA in the presence of ferricenium hexafluorophos-
phate. Recordings were done at 303 nm and 260 nm, respectively
488 J Inherit Metab Dis (2010) 33:479–494patients homozygous for the c.985A>G mutation. The
finding of a virtually full deficiency of MCAD in both
fibroblasts and lymphocytes of patients homozygous for the
985A>G mutation (Fig. 6) allows easy discrimination
between controls and patients and inspired us to propose
direct analysis of MCAD in lymphocytes in neonates with a
positive neonatal screening result for MCAD, as a first-line
test next to acylcarnitine analysis in a new blood sample.
Figure 7 shows our results obtained in 2007 and 2008, the
first two years of the Dutch extended neonatal screening
program. The results for the 16 neonates with a positive
screening result for MCADD in 2007 show that 11 of the
16 neonates analyzed by us were clearly MCAD-deficient.
In the remaining 5 neonates, MCAD activities were not
deficient, with activities ranging between 40 and 180%
(Fig. 7a). In 2008, 10 of the 15 neonates suspected to have
MCADD were clearly MCAD-deficient, whereas a fully
normal activity was found in neonate 15. Four out of the 15
neonates had intermediate values for MCAD in lympho-
cytes ranging from 21% in neonate 11 to 39% in neonate 14
(Fig. 7b). Neonates 13 and 14 turned out to be true
heterozygotes for MCADD. Detailed follow-up studies in
fibroblasts from neonates 11 and 12, however, revealed that
both had true MCAD-deficiency, albeit mild. This was
concluded from the results of the palmitate loading test in
which cells are loaded with palmitate followed by acylcar-
nitine profiling (Ventura et al. 1999), which revealed an
abnormal profile with a mildly elevated octanoylcarnitine
level. Furthermore, measurement of MCAD-activity in
fibroblasts from neonates 11 and 12 revealed clear
deficiencies. Molecular analysis revealed mutations in both
MCAD alleles in these patients. A full account of these data
will be published separately.
The same strategy is used for the follow-up of neonates
with a positive VLCAD screening result. Figure 8 shows
the results obtained in 2007 and 2008 with respect to
neonates with an abnormal acylcarnitine profile pointing to
VLCAD deficiency as detected upon neonatal screening. In
2007, only one neonate was identified in the Netherlands
with a positive screening result suggestive for VLCADD.
We received blood from this neonate, isolated lymphocytes,
and found a partial deficiency pointing to mild VLCAD-
deficiency (Fig. 8). In 2008, three neonates were picked up
by neonatal screening with an acylcarnitine profile sugges-
tive for VLCAD. In two of these neonates, VLCAD was
measured in lymphocytes with clear deficiencies in both of
them (Fig. 8).
Short-chain 3-hydroxyacyl-CoA dehydrogenase
The activity of the different 3HADs is usually measured in
the reverse direction because the equilibrium of the 3HAD-
reaction drives the reaction backwards, unless the product
of the 3HAD-reaction is constantly metabolized via the
direct and continuous thiolytic cleavage of the 3-ketoacyl-
CoA ester, the product of the 3HAD-reaction. 3HAD
activities can simply be measured by following the 3-
ketoacyl-CoA ester-dependent consumption of NADH at
340 nm. Fortunately, the activity of SCHAD can be
measured directly in skin fibroblast and lymphocyte
homogenates using acetoacetyl-CoA as substrate.
Acetoacetyl-CoA is unique for SCHAD, because the
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this substrate (Fig. 4c). Indeed, in fibroblasts of genetically
proven SCHAD-deficient patients, the 3HAD-activity as
measured with acetoacetyl-CoA was almost fully deficient,
as shown in Fig. 9a for the two established SCHAD-
deficient patients (siblings) identified by Molven et al.
(2004) with intermediate activities in fibroblasts from the
parents. A similar marked deficiency of SCHAD was found
in lymphocytes from the only patient with proven SCHAD-
deficiency we have analyzed so far (Fig. 9b).
Long-chain 3-hydroxyacyl-CoA dehydrogenase
Unfortunately, a specific substrate only reacting with the
LCHAD-component of MTP has not yet been identified. In
our hands, 3-ketopalmitoyl-CoA is the best substrate for
LCHAD at present. In fibroblasts, about 75% of the activity
as measured with 3-ketopalmitoyl-CoA is catalyzed by
LCHAD, whereas the remaining 25% is derived from
SCHAD. We have searched for methods allowing the assay
to be more specific. One method involves the selective
immunoprecipitation of SCHAD from homogenates prior to
enzymatic analysis using antibodies raised against SCHAD.
Although the method works fine in practice, we prefer the
second method we devised which is based on the finding
that N-ethylmaleimide, a SH-reagent, is a powerful inhib-
itor of LCHAD with no effect on SCHAD (IJlst and
Wanders 1993b). In practice, this means that we measure
the 3-ketopalmitoyl-CoA dehydrogenase activity in the
absence and presence of N-ethylmaleimide. The difference
between the two rates then represents true LCHAD-activity.
Figure 10a, b shows the results of such LCHAD-activity
measurements in fibroblasts (Fig. 10a) and lymphocytes
(Fig. 10b) from 8 and 5 genetically proven LCHADD-
patients, respectively.
3-Ketoacyl-CoA thiolases
The most popular assay for measurement of KAT activities
is that in which the consumption of the 3-ketoacyl-CoA
ester is measured spectrophotometrically at 303 nm. The
method is based on the notion that 3-ketoacyl-CoAs absorb
at 303 nm, when magnesium ions are present. As discussed
before, mitochondria contain at least three different thio-
lases of which the short-chain thiolase with 2-
methylacetoacetyl-CoA as specific substrate is inactive in
the absence of potassium ions. Furthermore, MCKAT is
fully inactive with 3-ketopalmitoyl-CoA (see Fig. 4d)s o
that the thiolase activity of MTP can be measured
specifically by using 3-ketopalmitoyl-CoA as substrate in
a medium lacking potassium ions.
ETF-alpha, ETF-beta and ETF-dehydrogenase
Although ETF-alpha, ETF-beta, and ETF-dehydrogenase are
strictly speaking not directly involved in fatty acid beta-
oxidation, they do play an essential role by transferring the
electrons coming from the acyl-CoA dehydrogenases to the
respiratory chain at the level of coenzyme Q. Measurement of
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been difficult. In order to measure ETF-dehydrogenase, for
instance, purified ETF is required. In our laboratory, we favor
direct sequence analysis of the ETFA, ETFB,a n dETFDH
genes in any patients suspected to suffer from glutaric aciduria
type 2 based on urinary organic acid analysis and/or
acylcarnitine analysis. Sequence analysis of these genes is
available in our laboratory. It should be noted that direct
enzymatic analysis of ETF and ETF-DH is operational in
other laboratories including the Lyon-lab, headed by Christine
Vianey-Saban (personal communication).
Whole cell fatty acid oxidation studies
Since acylcarnitine profiling in plasma from patients may
be so stunningly predictive in terms of which enzyme or
transporter is deficient (Fig. 2), whole cell fatty acid
oxidation studies have lost its importance as a first line
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Table 3 List of enzymatic and molecular tests as available for the mitochondrial beta-oxidation deficiencies
Enzyme Enzymatic testing Molecular testing
Lymphocytes Fibroblasts
Fresh Frozen
1. Plasma membrane carnitine transporter (OCTN2) + – ++
2. Carnitine palmitoyltransferase 1 (CPT1) + – ++
3. Mitochondrial carnitine/acylcarnitine translocase (CACT) + – ++
4. Carnitine palmitoyltransferase 2 (CPT2) + + + +
5. Very-long-chain acyl-CoA dehydrogenase (VLCAD) + + + +
6. Medium-chain acyl-CoA dehydrogenase (MCAD) + + + +
7. Short-chain acyl-CoA dehydrogenase (SCAD) + + + +
8. Isolated long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) + + + +
9. Isolated long-chain 3-ketothiolase (LCKAT) + + + +
10. Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) + + + +
11. Medium-chain 3-ketoacyl-CoA thiolase (MCKAT) –– + –
12. ETF dehydrogenase (ETFDH) –* –* –*+
13. ETF-alpha (ETFα) –* –* –*+
14. ETF-beta (ETFβ) –* –* –*+
+ Test available in our laboratory; – test not available in our laboratory; for more details see: www.labgmd.nl, –* test available in other
laboratories (see text)
J Inherit Metab Dis (2010) 33:479–494 491test. Rather, fatty acid oxidation studies are only done if
direct enzymatic analysis has not led to the identification of
the enzyme defect. Furthermore, whole cell fatty acid
oxidation studies are warranted to determine the effect of
a certain deficiency of an enzyme on flux through the
mitochondrial beta-oxidation system. This is especially
relevant in case of partial enzyme deficiencies as found in
patients picked up by neonatal screening programs as
described above from MCADD (Fig. 7).
Through the years, many different methods have been
set up for this purpose, including: (1) [
14C]-CO2 release
assays using different [1-
14C]- or [U-
14C]-labelled fatty
acids; (2) tritium release assays using different [
3H]-labelled
fatty acids, notably [9,10-
3H]-myristic acid, [9,10-
3H]-
palmitic acid, and [9,10-
3H]-oleic acid (Manning et al.
1990; Olpin et al. 1992, 1997); and (3) quantitative acyl-
CoA and acylcarnitine profiling studies. The latter methods
have been pioneered by Bartlett and co-workers in the late
1980sduring studies on the beta-oxidation offatty acids in rat
liver mitochondria. The methodology involved incubation of
mitochondria with radiolabeled fatty acids followed by
extraction of the acyl-CoA esters followed by separation on
radio-HPLC with continuous on-line monitoring of radioac-
tively labeled acyl-CoAs (Watmough et al. 1988, 1989).
These methods were later improved and extended to
include the analysis of both acyl-CoA esters and acylcarni-
tines, and were subsequently used to study mitochondrial
fatty acid oxidation in fibroblasts from patients first using
mitochondria isolated from fibroblasts (Kler et al. 1991)
and later using selectively permeabilized fibroblasts
(Pourfarzam et al. 1994) and peripheral blood cells
(Schaefer et al. 1995).
In 1995, Roe and co-workers (Nada et al. 1995)
published an elegant method named the acylcarnitine
profiling method which involves incubation of intact
fibroblasts or lymphoblastoid cells with a deuterated long-
chain fatty acid ([17,17,18,18-
2H4]-linoleic acid) followed
by analysis of the acylcarnitines using tandem-mass
spectrometry. The profiles are often very characteristic
which immediately guides the way to the underlying defect.
Several variations on this theme have been published by
different groups the main difference being the use of
differentially labelled fatty acids including [16-
2H3]-pal-
mitic acid (Vianey-Saban et al. 1998), [U-
13C]-palmitic acid
(Ventura et al. 1999), and [15,15,16,16,16-
2H5]-palmitic
acid (Sim et al. 2002; Law et al. 2007).
We have been using the acylcarnitine profiling method
with [U-
13C] palmitic acid as substrate (Ventura et al. 1999)
and the tritium-release assays using tritiated oleic acid for
many years now. The reason for subjecting each patient cell
line to both these assays is that the tritium-release assay
measures the actual rate of fatty acid oxidation with no
information on the site of the enzyme block whereas the
reverse is true for the acylcarnitine profiling methods,
which do provide information on the site of the enzymatic
block. Recently, Law et al. (2007) devised an elegant
method which couples acylcarnitine profiling via ESI/MS/
MS with the simultaneous measurement of the flux through
the beta-oxidation pathway, using [
2H31]-palmitic acid. The
rate of fatty acid oxidation was measured from the
deuterated water enrichment by means of isotope ratio MS.
It should be emphasized that there is still room for
improvement of the currently available whole cell assays
since patients with a mild defect in mitochondrial fatty acid
oxidation may show no abnormalities in either of the two
tests (results not shown). We have experienced this through
the years especially in patients with mild deficiencies at the
level of VLCAD and LCHAD/MTP, as well as in mild
glutaric aciduria type 2 patients. We are continuing our
efforts to improve these methods.
Conclusions
Much has been learned in recent years about the
enzymatic and molecular basis of the different mito-
chondrial beta-oxidation deficiencies. The fact that
many, if not all, enzymes of mitochondrial fatty acid
oxidation are also expressed in peripheral blood cells
allows the rapid identification of the enzymatic defect in
patients, suspected to suffer from a FAO disorder on the
basis of an abnormal acylcarnitine profile upon neonatal
screening or otherwise. Miniaturization of existing
enzyme assays may even allow identification of patients
using blood spots. Efforts to realize this option are
underway. Table 3 provides information on the full series
of enzymatic and molecular tests currently available in our
laboratory (see also www.labgmd.nl).
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